| |
 |
Free to registered subscribers, with
no fees or prerequisites required |
| |
A monthly review of
journal literature by key topics, with access to available abstracts
and full text articles |
| |
Timely commentary on current research,
best practices and clinical management issues, provided by an expert
panel of Cystic Fibrosis Specialists |
| |
7 bi-monthly newsletters and 5 alternating podcasts (audio interviews on related to key topics) |
| |
Delivered directly to your email box |
| |
Certified for credit – earn your
CME/CE credits online |
After completing this activity, the participant will demonstrate the ability to: |
| |
Evaluate new and emerging disease modifying CF treatments and appropriate clinical strategies for their use. |
| |
Explain the importance of controlling environmental modifiers of CF lung disease and the latest clinically relevant data regarding generic modifiers. |
| |
Demonstrate a comprehensive foundational knowledge of P. aeruginosa. |
|
Distinguish between existing and newly available antibiotic agents, alone or as combination therapy. |
|
Adequately manage pulmonary exacerbations. |
|
Identify factors and appropriate precautions to slow the incidence of Multiple Antibiotic-Resistant P. aeruginosa (MARPA). |
|
Incorporate evidence-based strategies to improve patient adherence to antibiotic medications. |
|
Incorporate evidence-based strategies to improve PERT adherence. |
|
Implement better patient nutrition plans. |
| |
|
